Citigroup
JBIO icon

Citigroup’s Jade Biosciences JBIO Stock Holding History

Citigroup’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$468K Sell
33,298
-21,082
-39% -$423K ﹤0.01% 3798
2026
Q2 		$1.21M Buy
54,380
+46,764
+614% +$975K ﹤0.01% 3311
2026
Q1 		$107K Buy
7,616
+6,281
+470% +$90.9K ﹤0.01% 4259
2025
Q4 		$20.6K Sell
1,335
-257
-16% -$3.02K ﹤0.01% 4863
2025
Q3 		$13.7K Sell
1,592
-10,551
-87% -$86.2K ﹤0.01% 4931
2025
Q2 		$121K Buy
12,143
+11,652
+2,373% +$397K ﹤0.01% 4319
2025
Q1 		$43.1K Buy
491
+28
+6% +$2.46K ﹤0.01% 4915
2024
Q4 		$43K Sell
463
-6,206
-93% -$535K ﹤0.01% 5125
2024
Q3 		$488K Buy
6,669
+6,568
+6,503% +$424K ﹤0.01% 3743
2024
Q2 		$5.88K Buy
101
+28
+38% +$18.6K ﹤0.01% 5235
2024
Q1 		$75.3K Buy
73
+13
+22% +$9.9K ﹤0.01% 4420
2023
Q4 		$47.4K Buy
60
+54
+900% +$27.5K ﹤0.01% 4550
2023
Q3 		$2.89K Sell
6
-89
-94% -$48.2K ﹤0.01% 4865
2023
Q2 		$57K Buy
95
+88
+1,257% +$56.3K ﹤0.01% 4565
2023
Q1 		$4.62K Sell
7
-3
-30% -$2.49K ﹤0.01% 4961
2022
Q4 		$10.2K Sell
10
-5
-33% -$3.63K ﹤0.01% 4831
2022
Q3 		$8K Sell
15
-16
-52% -$10.7K ﹤0.01% 5054
2022
Q2 		$17K Sell
31
-10
-24% -$4.78K ﹤0.01% 5089
2022
Q1 		$26K Sell
41
-58
-59% -$22.5K ﹤0.01% 5016
2021
Q4 		$41K Buy
99
+66
+200% +$33.4K ﹤0.01% 5156
2021
Q3 		$24K Buy
+33
New +$18.5K ﹤0.01% 5148

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Citigroup's JBIO Position: Q3 2026 in Review

Citigroup reduced its Jade Biosciences (JBIO) stake by 39% in Q3 2026, selling an estimated $423K and leaving 33,298 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #3798.

Citigroup first reported a position in JBIO in Q3 2021 and has held it in 21 quarters since. The position peaked at $1.21M in Q2 2026. 73 funds tracked by Wall St. Rank hold JBIO as of Q3 2026.

  • Citigroup held 33,298 shares of Jade Biosciences worth $468K as of Q3 2026.
  • Citigroup sold 21,082 Jade Biosciences shares in Q3 2026, an estimated $423K.
  • Jade Biosciences made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3798 holding.
  • Citigroup first reported a position in Jade Biosciences in Q3 2021 and has held it in 21 quarters since.
  • Citigroup's Jade Biosciences position peaked at $1.21M in Q2 2026.
  • 73 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.